HFA Premium Access

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

Presentation

About the speaker

Doctor Oriol Iborra Egea

Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona (Spain)
1 presentation
0 follower

9 more presentations in this session

Real world analysis of outcomes of remote pulmonary artery hemodynamic monitoring in overweight and obese patients with heart failure

Speaker: Doctor M. Oberoi (Sioux Falls, US)

Thumbnail

Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study.

Speaker: Doctor J. Garcia-Pinilla (Malaga, ES)

Thumbnail

HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

Speaker: Mr J. Yang (South San Francisco, US)

Thumbnail

Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies

Speaker: Doctor K. Jering (Boston, US)

Thumbnail

Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)

Speaker: Doctor J. Ezekowitz (Edmonton, CA)

Thumbnail

Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 1

Speakers: Doctor O. Iborra Egea, Doctor M. Oberoi, Doctor J. Garcia-Pinilla, Mr J. Yang, Doctor K. Jering...
Thumbnail

About the event

Image

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Related content

ESC Premium Access

EMPEROR-Pooled: effect of empagliflozin on serious adverse renal outcomes in chronic heart failure – a prospective alpha-protected, Individual patient-level pooled analysis

27 August 2021

ESC Premium Access

EMPEROR-Preserved - Discussant review.

27 August 2021

ESC Premium Access

EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes

27 August 2021

This platform is supported by

logo Novo Nordisk